SAB Biotherapeutics, a clinical-stage biopharmaceutical company, will release its first quarter 2026 financial results on May 12, 2026. The company will hold a conference call and webcast at 8:30 AM ET to discuss the results and provide updates on its development of SAB-142, a treatment for type 1 diabetes and autoimmune diseases. SAB BIO uses proprietary genetic engineering technology to produce human immunoglobulin G for immune disorders. Investors and interested parties can access the live call by registration, with a replay available on the company's website afterward.
JOYY Inc. posted a 12.4% year-over-year revenue increase to $555.7 million in Q1 2026, driven by growth in social entertainment, BIGO Ads, and SHOPLINE e-commerce segments. BIGO Ads revenue surged 55.6%, while SHOPLINE grew 16.1%. The company also an...
Silvercorp Metals Inc. has submitted an application for a triple primary listing of its common shares on the Hong Kong Stock Exchange's Main Board, accompanied by a global offering of shares. This move aims to expand the company's investor base and e...
Archax, the UK's first FCA-regulated digital securities exchange, is integrating its tokenization platform with the Aptos blockchain, bringing over 100 regulated tokenized securities and real-world assets onchain. The first product launched is the Me...
Circle has raised $222 million to develop Arc, its own layer-one blockchain designed to host its USDC stablecoin as the native asset. This move shifts Circle from just issuing stablecoins to owning the infrastructure they settle on, creating a potent...
Last week, spot Bitcoin ETFs experienced significant net outflows totaling $1.257 billion, the largest weekly outflow since December 2025. BlackRock’s IBIT led the outflows with $448.4 million withdrawn. This outflow coincided with a Bitcoin price dr...
